SueWallSt
SueWallSt
Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how the powerful play the game and sometimes get burned. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Go to ZLK.com for more on the case and follow us for the next corporate faceplant.
Author
SueWallSt
Category
Podcast website
Latest episode
Jun 25, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
#136 $COTY Beauty Boom to Bust The Earnings Shock Story 01.05.2026 15:05
In this episode, we break down the rise and reality check behind Coty Inc $COTY, uncovering a high stakes securities case tied to beauty industry trends, earnings guidance, and investor expectations. Built for investors, traders, and market watchers, this deep dive explores fragrance sales, Consumer Beauty struggles, margin pressure, and stock volatility. Expect sharp analysis, financial storytell...
#135 $CIGL From Sky High Hype to Crash Landing The Concorde Collapse 01.05.2026 12:41
This episode breaks down the explosive rise and سقوط of Concorde International Group $CIGL, blending true crime style storytelling with deep dive financial analysis. Built for retail investors, traders, and anyone navigating stock market risk, we unpack alleged WhatsApp scams, social media manipulation, low float stocks, and pump and dump dynamics. Expect investigative commentary, market insights,...
#134 $ATRA From Breakthrough to Breakdown The Atara Biotech Story 01.05.2026 14:55
Dive into a gripping finance and biotech podcast episode unpacking Atara Biotherapeutics and the fall from FDA optimism to a securities class action. Perfect for investors, traders, and finance enthusiasts, this episode blends deep dive analysis, storytelling, and market insight. We explore $ATRA stock, FDA setbacks, manufacturing risks, and investor impact. Visit ZLK.com for more info. Add our Wh...
#133 $IT Strong Guidance or Silent Slowdown Inside Gartner Miss 03.04.2026 14:47
Dive into the Gartner $IT controversy as we break down a securities class action tied to contract value growth, consulting revenue weakness, and alleged misleading guidance. This episode is for investors, traders, and anyone following tech services, enterprise demand, and market risk. Expect deep dives, real case analysis, and insights into slowing sales cycles, missed expectations, and sharp stoc...
#132 $GO Growth Push or Costly Correction Inside Grocery Outlet Drop 02.04.2026 13:03
Dive into the Grocery Outlet $GO controversy as we break down a securities class action tied to rapid store expansion, restructuring risks, and alleged misleading growth claims. This episode is for investors, traders, and anyone following retail stocks, expansion strategies, and market volatility. Expect deep dives, real case analysis, and insights into store closures, impairment charges, and stoc...
#131 $ALIT Dividend Confidence or Collapse Inside Alight Unraveling 02.04.2026 17:09
Dive into the Alight $ALIT controversy as we break down a securities class action tied to execution failures, weak growth, and alleged misleading statements about margins and dividends. This episode is for investors, traders, and anyone following SaaS, HR tech, and market risk. Expect deep dives, real case analysis, and insights into leadership exits, guidance cuts, and stock crashes. Visit ZLK.co...
#130 $TCOM Antitrust Risk or Missed Warning Inside Trip.com Drop 02.04.2026 14:37
Dive into the Trip.com $TCOM controversy as we break down a securities class action tied to antitrust investigations, regulatory risk in China, and alleged misleading disclosures. This episode is for investors, traders, and anyone following tech platforms, global markets, and market volatility. Expect deep dives, real case analysis, and insights into regulatory scrutiny, risk disclosures, and stoc...
#129 $SLNO Breakthrough Drug or Hidden Risk Inside Soleno Fallout 01.04.2026 14:02
Dive into the Soleno Therapeutics $SLNO controversy as we break down a securities class action tied to drug safety, rare disease treatments, and alleged misleading statements around Vykat XR. This episode is for investors, traders, and anyone following biotech stocks, FDA approvals, and market risk. Expect deep dives, real case analysis, and insights into safety concerns, patient outcomes, and sto...
#128 $ODD Beauty Tech or Broken Ads Inside Oddity Tech Shock 01.04.2026 14:32
Dive into the Oddity Tech $ODD controversy as we break down a securities class action tied to digital advertising, customer acquisition costs, and algorithm driven disruptions. This episode is for investors, traders, and anyone following ecommerce, tech stocks, and market risk. Expect deep dives, real case analysis, and insights into ad auction dynamics, rising costs, and sudden stock drops. Visit...
#127 $NKTR Trial Trouble When Clinical Confidence Cracks 01.04.2026 12:51
Dive into the Nektar Therapeutics $NKTR controversy as we break down a securities class action tied to biotech trials, protocol violations, and alleged misleading statements around clinical execution. This episode is for investors, traders, and anyone following biotech stocks, drug development, and market risk. Expect deep dives, real case analysis, and insights into trial integrity, statistical o...
#126 $MNDY Growth Story or Slowing Momentum Inside monday.com Shift 31.03.2026 14:21
Dive into the monday.com $MNDY controversy as we break down a securities class action tied to SaaS growth, enterprise sales trends, and shifting long term revenue targets. This episode is for investors, traders, and anyone following tech stocks, cloud platforms, and market volatility. Expect deep dives, real case analysis, and insights into slowing customer growth, longer sales cycles, and guidanc...
#125 $EOSE Battery Boom or Broken Ramp Inside Eos Energy Miss 31.03.2026 14:41
Dive into the Eos Energy $EOSE controversy as we break down a securities class action tied to battery technology, manufacturing automation, and missed revenue guidance. This episode is for investors, traders, and anyone following energy storage, clean tech, and market risk. Expect deep dives, real case analysis, and insights into production delays, downtime issues, and stock drops. Visit ZLK.com f...
#124 $DRVN Restatement Shock When Financials Can’t Be Trusted 31.03.2026 14:04
Dive into the Driven Brands $DRVN controversy as we break down a securities class action tied to financial restatements, internal control failures, and accounting errors across multiple years. This episode is for investors, traders, and anyone following earnings quality, corporate governance, and market risk. Expect deep dives, real case analysis, and insights into unreliable financials, audit iss...
#123 $CWH Inventory Control or Margin Collapse Inside Camping World 30.03.2026 12:24
Dive into the Camping World $CWH controversy as we break down a securities class action tied to inventory management, margin pressure, and alleged misleading statements about financial discipline. This episode is for investors, traders, and anyone following retail stocks, RV market trends, and market risk. Expect deep dives, real case analysis, and insights into inventory missteps, declining margi...
#122 $CHOW Pump Hype or Engineered Collapse Inside ChowChow Cloud 30.03.2026 14:47
Dive into the ChowChow Cloud $CHOW controversy as we break down a securities class action tied to IPO activity, alleged stock manipulation, and social media driven trading schemes. This episode is for investors, traders, and anyone following micro cap stocks, IPO risks, and market volatility. Expect deep dives, real case analysis, and insights into pump and dump patterns, low float risks, and sudd...
#121 $BSX Heart Growth Hype or Hidden Slowdown Inside Boston Scientific 30.03.2026 8:45
Dive into the Boston Scientific $BSX controversy as we break down a securities class action tied to medical devices, electrophysiology growth, and alleged misleading statements around FARAPULSE adoption. This episode is for investors, traders, and anyone following healthcare stocks, medtech innovation, and market risk. Expect deep dives, real case analysis, and insights into competition, slowing p...
#120 $AQST FDA Delay Shock The Allergy Drug Setback Investors Missed 29.03.2026 8:29
Dive into the Aquestive Therapeutics $AQST controversy as we break down a securities class action tied to biotech approvals, FDA delays, and alleged misleading timelines around Anaphylm. This episode is for investors, traders, and anyone following biotech stocks, drug approvals, and market volatility. Expect deep dives, real case analysis, and insights into regulatory risk, clinical setbacks, and...
#119 $APO Wall Street Secrets The Apollo Epstein Controversy 29.03.2026 9:19
Dive into the Apollo Global Management $APO controversy as we break down a securities class action tied to alleged undisclosed ties, reputational risk, and investor disclosures. This episode is for investors, traders, and anyone following hedge funds, Wall Street news, and market transparency. Expect deep dives, real case analysis, and insights into corporate governance, disclosure risks, and stoc...
#118 $SNOW Cloud Growth or Hidden Headwinds Inside the Snowflake Drop 29.03.2026 8:35
Dive into the Snowflake $SNOW controversy as we break down a securities class action tied to cloud computing, consumption based revenue, and unexpected growth headwinds. This episode is for investors, traders, and anyone following tech stocks, data platforms, and market volatility. Expect deep dives, real case analysis, and insights into pricing models, efficiency impacts, and stock drops. Visit Z...
#117 $NAVN IPO Turbulence What Investors Weren’t Told 28.03.2026 8:56
Dive into the Navan $NAVN controversy as we break down a securities class action tied to IPO disclosures, rising sales and marketing costs, and post IPO stock declines. This episode is for investors, traders, and anyone following tech stocks, IPOs, and market risk. Expect deep dives, real case analysis, and insights into financial transparency, growth metrics, and investor expectations. Visit ZLK....
#116 $LAKE Growth Strategy or Cracks in the Foundation Inside Lakeland Fallout 28.03.2026 9:19
Dive into the Lakeland Industries $LAKE controversy as we break down a securities class action tied to acquisitions, operational challenges, and missed financial guidance. This episode is for investors, traders, and anyone following industrial stocks, M and A strategies, and market risk. Expect deep dives, real case analysis, and insights into earnings misses, supply chain issues, and stock declin...
#115 $FBRT Dividend Cut Shock Income Investors Blindsided 28.03.2026 9:00
Dive into the Franklin BSP Realty Trust $FBRT controversy as we break down a securities class action tied to REIT dividends, commercial real estate debt, and alleged misleading statements about earnings power. This episode is for income investors, traders, and anyone following dividend stocks, REITs, and market risk. Expect deep dives, case analysis, and insights into dividend cuts, earnings press...
#114 $CORT FDA Shock The Approval That Never Came 27.03.2026 8:19
Dive into the Corcept Therapeutics $CORT controversy as we break down a securities class action tied to biotech approvals, FDA setbacks, and alleged misleading statements حول relacorilant. This episode is for investors, traders, and anyone following biotech stocks, clinical trials, and market volatility. Expect deep dives, case analysis, and insights into FDA risk, insider selling, and stock crash...
#113 $ZYXI Shocking Growth or Alleged Fraud Inside Zynex Collapse 27.03.2026 8:51
Dive into the Zynex $ZYXI controversy as we break down a massive securities class action tied to alleged overbilling, medical device supply practices, and inflated revenue growth. This episode is for investors, traders, and anyone following healthcare stocks, fraud allegations, and market risk. Expect deep dives, real case analysis, and insights into billing practices, regulatory scrutiny, and sto...
#112 $ENPH Solar Shock Inventory Truth or Revenue Illusion 27.03.2026 7:26
Unpack the Enphase Energy $ENPH controversy as we break down a securities class action tied to solar energy, inventory management, and tax credit impacts. This episode is built for investors, traders, and anyone tracking clean energy stocks, earnings volatility, and market risk. We dive into safe harbor revenue, channel inventory concerns, and shifting guidance with sharp analysis and real case in...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.